药用明胶市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球药用明胶市场规模达13亿美元，预计到2034年将以5.8%的复合年增长率成长，达到23亿美元。胶囊和片剂等口服固体剂型的消费量不断增长，有力地推动了市场发展势头。随着慢性病发生率的上升，製药业也随之扩张，对明胶基辅料的需求也持续成长。明胶能够包覆多种活性药物成分，是硬胶囊和软胶囊配方中的关键成分。它与亲水性和亲脂性化合物的优异相容性，提高了最终产品的生物利用度，使其成为现代药物传递中不可或缺的辅料。

药用明胶是一种精製蛋白质，源自于动物骨骼和皮肤等胶原蛋白来源。它因其独特的物理和化学特性而被广泛使用，包括热可逆性、生物相容性和易消化性。这些特性使其成为製造胶囊、包衣剂、伤口敷料和其他医疗製剂的理想材料。随着製药公司越来越注重提高产品的功效和稳定性，明胶作为辅料的作用比以往任何时候都更加重要。创新药物剂型的稳定发展和先进给药系统的开发也促使整个产业对药用级明胶的依赖日益增加。药用明胶的主要生产商在保持稳定的品质、遵守监管准则以及提供客製化解决方案以满足不断变化的配方需求方面发挥着至关重要的作用。

就产品类型而言，药用明胶市场分为A型明胶和B型明胶。其中，B型明胶在2024年占据主导地位，约占整体市占率的65.4%。其被广泛采用的主要原因之一是其经济高效的生产过程。 B型明胶通常经过碱性水解处理，使其具有良好的特性，例如高热稳定性和接近中性的pH值。这些特性使其特别适用于製药用途，包括胶囊壳、薄膜包衣和注射。此外，其在药品生产环境中的可预测性能确保了药品的均匀性和质量，而这些是大规模药品生产的关键参数。因此，对于寻求可靠性和多功能性辅料的配方师来说，B型明胶仍然是首选。

市场进一步细分，基于明胶的来源，包括牛、猪、鱼和家禽。其中，牛源明胶在2024年占最大份额，市占率达48.4%。预计预测期内，该市场将以6.1%的复合年增长率成长。由于广泛的养牛业，牛源明胶拥有稳定且充足的原料供应。其强大的凝胶强度、高黏度以及在不同加工条件下优异的稳定性，使其特别适用于各种製药应用。这些应用不仅包括胶囊製造，还可用于血浆扩容剂和伤口护理产品。牛明胶始终如一的品质和可重复性进一步提升了其在确保标准化配方结果方面的价值。

从区域来看，北美在全球药用明胶市场中占据主导地位，收入贡献最高，2024 年占 38.2% 的市场份额。该地区的主导地位主要归功于其先进的药品生产基础设施以及严格且支持性强的合规环境。由于明胶性能可靠且适应性强，北美製药公司积极将其整合到各种剂型中。此外，製药业持续的研发投入也促进了基于明胶的先进药物输送解决方案的出现。完善的合约製造组织生态系统进一步增强了区域市场，有助于满足国内和全球需求。

全球药用明胶市场呈现中等整合格局。这些参与者凭藉全球製造能力、严格遵守品质标准以及持续的产品开发创新，保持着竞争优势。他们专注于提昇明胶的功能特性，以用于特殊配方（例如控释胶囊或可吸收手术辅助器具），从而拓展了市场深度。同时，发展中地区的新进业者也透过提供经济高效的明胶选择、建立认证设施以及瞄准渗透率较低的市场的新兴需求，展现出其影响力。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 胶囊和软胶囊的需求不断增长
    • 老年人口增长与慢性病负担
    • 明胶在止血剂和伤口护理的应用
    • 疫苗和生物製剂产量不断成长
  • 产业陷阱与挑战
    • 动物源性明胶对人体的副作用
    • 植物基和合成替代品的出现
  • 市场机会
    • 在再生医学和组织工程的应用
    • 发展中国家对药用明胶的需求不断成长
• 成长潜力分析
• 监管格局
• 技术进步
  • 当前的技术趋势
  • 新兴技术
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
  • 北美洲
  • 欧洲
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 扩张计划

第五章：市场估计与预测：按类型，2021 - 2034 年

• 主要趋势
• A型
• B型

第六章：市场估计与预测：按来源，2021 - 2034 年

• 主要趋势
• 猪
• 牛
• 鱼
• 家禽

第七章：市场估计与预测：按功能，2021 - 2034 年

• 主要趋势
• 稳定剂
• 增稠剂
• 胶凝剂
• 成膜
• 黏附性
• 其他功能

第八章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 胶囊
  • 硬胶囊
  • 软胶囊
• 平板电脑
• 可吸收止血钳
• 其他应用

第九章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Capsugel (Lonza)
• Funingpu Biotechnology
• Gelita AG
• India Gelatine & Chemicals
• ITALGEL
• Junca Gelatines
• Lapi Gelatine
• Nitta Gelatin
• Rousselot (Darling Ingredients)
• Sterling Biotech
• PB Leiner (Tessenderlo Group)
• Trobas Gelatine
• Weishardt Group
• Xiamen Gelken Gelatin

The Global Pharmaceutical Gelatin Market was valued at USD 1.3 billion in 2024 and is estimated to grow at a CAGR of 5.8% to reach USD 2.3 billion by 2034. Market momentum is being strongly driven by the growing consumption of oral solid dosage forms like capsules and tablets. As the pharmaceutical industry expands in response to rising incidences of chronic diseases, the need for gelatin-based excipients continues to rise. Gelatin is a key component used in the formulation of both hard and soft capsules, thanks to its ability to encapsulate a wide range of active pharmaceutical ingredients. Its superior compatibility with hydrophilic and lipophilic compounds enhances the bioavailability of the final product, making it indispensable in modern drug delivery.

Pharmaceutical gelatin is a refined protein derived from collagen sources such as animal bones and skins. It is commonly used for its unique physical and chemical properties, including thermal reversibility, biocompatibility, and ease of digestibility. These features make it an ideal material for manufacturing capsules, coating agents, wound dressings, and other medical formulations. With pharmaceutical companies increasingly focused on improving the efficacy and stability of their products, gelatin's role as an excipient has become more important than ever. The steady shift toward innovative drug formats and the development of advanced delivery systems have also contributed to the growing reliance on pharmaceutical-grade gelatin across the industry. Major producers of pharmaceutical gelatin play a crucial role in maintaining consistent quality, adhering to regulatory guidelines, and offering tailored solutions to meet evolving formulation needs.

In terms of product types, the pharmaceutical gelatin market is divided into type A and type B gelatin. Among these, type B gelatin held a dominant position in 2024, accounting for approximately 65.4% of the overall market share. One of the main reasons for its broad adoption is its cost-effective manufacturing process. Type B gelatin is typically processed through alkaline hydrolysis, which imparts favorable characteristics such as high thermal stability and a nearly neutral pH. These properties make it especially suitable for pharmaceutical uses, including capsule shells, film coatings, and injectable formulations. Moreover, its predictable performance in drug manufacturing environments ensures uniformity and quality, which are critical parameters in large-scale pharmaceutical production. As a result, type B gelatin continues to be a preferred choice among formulators seeking reliability and versatility in excipient performance.

The market is further segmented based on the source of gelatin, which includes bovine, porcine, fish, and poultry. Among these, gelatin derived from bovine sources represented the largest segment in 2024, holding a market share of 48.4%. It is anticipated to expand at a CAGR of 6.1% during the forecast period. Bovine-derived gelatin benefits from a stable and abundant supply of raw materials, thanks to widespread cattle farming. Its strong gelling strength, high viscosity, and excellent stability across processing conditions make it particularly suitable for a wide array of pharmaceutical applications. These include not just capsule manufacturing but also uses in plasma expanders and wound care products. The consistent quality and reproducibility of bovine gelatin further enhance its value in ensuring standardized formulation outcomes.

Regionally, North America led the global pharmaceutical gelatin market with the highest revenue contribution, securing a 38.2% market share in 2024. The dominance of this region is largely attributed to its advanced pharmaceutical production infrastructure and a highly regulated yet supportive compliance environment. Pharmaceutical companies in North America actively integrate gelatin into a variety of dosage forms due to its proven performance and adaptability. Additionally, ongoing investment in research and development across the pharmaceutical landscape supports the emergence of sophisticated gelatin-based drug delivery solutions. A well-established ecosystem of contract manufacturing organizations further strengthens the regional market, helping meet both domestic and global demand.

The global pharmaceutical gelatin market exhibits a moderately consolidated structure. These players maintain their competitive edge through global manufacturing capabilities, strict adherence to quality standards, and consistent innovation in product development. Their focus on enhancing gelatin's functional properties for use in specialized formulations-such as controlled-release capsules or absorbable surgical aids-adds depth to the market. At the same time, newer entrants in developing regions are making their presence felt by providing cost-efficient gelatin options, establishing certified facilities, and targeting emerging demand across underpenetrated markets.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Source trends
  • 2.2.4 Function trends
  • 2.2.5 Application trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising demand for capsules and softgels
    • 3.2.1.2 Expanding elderly population and chronic disease burden
    • 3.2.1.3 Use of gelatin in hemostatic agents and wound care
    • 3.2.1.4 Growing vaccine production and biologics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects associated with animal-derived gelatin in humans
    • 3.2.2.2 Emergence of plant based and synthetic alternatives
  • 3.2.3 Market opportunities
    • 3.2.3.1 Use in regenerative medicine and tissue engineering
    • 3.2.3.2 Rising demand for pharma gelatin in developing countries
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technological advancements
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Type A
• 5.3 Type B

Chapter 6 Market Estimates and Forecast, By Source, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Porcine
• 6.3 Bovine
• 6.4 Fish
• 6.5 Poultry

Chapter 7 Market Estimates and Forecast, By Function, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Stabilizers
• 7.3 Thickeners
• 7.4 Gelling agents
• 7.5 Film forming
• 7.6 Adhesion
• 7.7 Other functions

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Capsules
  • 8.2.1 Hard capsules
  • 8.2.2 Soft capsules
• 8.3 Tablets
• 8.4 Absorbable hemostats
• 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Capsugel (Lonza)
• 10.2 Funingpu Biotechnology
• 10.3 Gelita AG
• 10.4 India Gelatine & Chemicals
• 10.5 ITALGEL
• 10.6 Junca Gelatines
• 10.7 Lapi Gelatine
• 10.8 Nitta Gelatin
• 10.9 Rousselot (Darling Ingredients)
• 10.10 Sterling Biotech
• 10.11 PB Leiner (Tessenderlo Group)
• 10.12 Trobas Gelatine
• 10.13 Weishardt Group
• 10.14 Xiamen Gelken Gelatin